The final day of trading with interim shares (paid, subscribed shares) is estimated to be 20 February 2007. The newly issued shares are estimated to be tradable on the OMX Nordic Exchange from Thursday, 1 March 2007. All the issue proceeds were used for amortisation payment of the bridge financing that was secured for the 3M acquisition. In the next phase, Meda will raise a medium-term loan facility through syndication in the bank market. • LONG-TERM LICENCE AGREEMENT IN THE CARDIOVASCULAR AREA WITH RECORDATI Meda and Recordati, an Italian pharma company, signed a long-term licence agreement for marketing Zaneril on the German market. Zaneril combines the substances lercanidipine and enalapril. Zaneril is well documented and indicated for treatment of high blood pressure.